Jul
09
The Private Equity Firm That Quietly Profits on Top-Selling Drugs
ByCashing in on rising drug prices often unleashes an outcry from consumers and politicians.
But a little-known private equity investor, Royalty Pharma, has built an unusual investment portfolio valued at $15 billion — it buys up the rights to royalties on future drug sales — while largely avoiding public controversy. By its own count, Royalty Pharma owns partial rights to seven of the 30 top-selling drugs in the United States, including giants like Humira, the arthritis treatment that is the single biggest-selling medication in America. And its deals have been getting larger…
The Private Equity Firm That Quietly Profits on Top-Selling Drugs
